CPHI Milano 2026 | Geyuan Tianrun Continues to Expand Global Pharmaceutical Partnerships

From October 6 to 8, 2026, CPHI Worldwide 2026 was grandly held at the Fiera Milano, the new international exhibition center in Milan, Italy. As one of the most influential industry events in the global pharmaceutical sector, this edition of the show was themed “Shaping the Future of Pharma,” covering the entire value chain—including APIs, biomanufacturing, CDMOs, and pharmaceutical equipment—while introducing specialized zones on AI-driven drug discovery and cold-chain pharmaceutical logistics. The event brought together over 2,400 exhibitors from 166 countries and regions and attracted 62,000 professional visitors for networking and business discussions.
 

   
As a national high-tech enterprise, Beijing Geyuan Tianrun Biotechnology Co., Ltd. made a strong showing at the exhibition with its full range of high-purity animal-derived enzymes and pharmaceutical APIs. At the show, the company’s technical and international trade teams welcomed professional visitors from around the world, systematically presenting their proprietary isolation and purification technologies, stable large-scale production capacity, and comprehensive export support solutions. Leveraging more than two decades of R&D and manufacturing expertise in the biochemical enzyme field, Geyuan Tianrun’s products have been supplied for the long term to over ten countries across Europe, North America, Southeast Asia, Japan, and South Korea, serving international pharmaceutical companies, CROs, and biological reagent manufacturers. Numerous overseas buyers engaged in in-depth discussions on-site regarding pharmaceutical-grade enzyme preparations, custom enzyme activity services, and long-term API contract manufacturing, expressing high praise for the company’s mature supply chain capabilities and rigorous GMP quality management system.

At this Milan trade show, Geyuan Tianrun is closely monitoring cutting-edge global trends in biopharmaceutical technology and actively exploring collaboration opportunities in areas such as green biomanufacturing and customized R&D services. The company will continue to deepen its presence in international markets, connecting with pharmaceutical partners worldwide through reliable products and services, and steadily advancing its global expansion strategy.